ArticleCancer medicine2017
Transcriptome analysis in primary colorectal cancer tissues from patients with and without liver metastases using next-generation sequencing.
Article in Cancer medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 30 citations in OpenAlex.
- SLC13A2-transported citrate remodels transcriptional regulation through protein acetylation to suppress tumor growth.Science advances · 2026Article
- Development and validation of a radiopathomics model for predicting liver metastases of colorectal cancer.European radiology · 2025Article
- Identification of novel diagnostic biomarkers associated with liver metastasis in colon adenocarcinoma by machine learning.Discover oncology · 2024Article
- Effect of intraoperative blood loss on postoperative complications and prognosis of patients with colorectal cancer: A meta‑analysis.Biomedical reports · 2024Article
- Identification of Molecular Targets of Bile Acids Acting on Colorectal Cancer and Their Correlation with Immunity.Digestive diseases and sciences · 2024Article
- Using machine learning approach for screening metastatic biomarkers in colorectal cancer and predictive modeling with experimental validation.Scientific reports · 2023Article
- Identification and validation of a pyroptosis-related prognostic model for colorectal cancer.Functional & integrative genomics · 2022Article
- Complement C5 is a novel biomarker for liver metastasis of colorectal cancer.Journal of gastrointestinal oncology · 2022Article
- Multi-OMICs data analysis identifies molecular features correlating with tumor immunity in colon cancer.Cancer biomarkers : section A of Disease markers · 2022Article
- Chemokines in progression, chemoresistance, diagnosis, and prognosis of colorectal cancer.Frontiers in immunology · 2022Review
- A novel prognostic model based on urea cycle-related gene signature for colorectal cancer.Frontiers in surgery · 2022Article
- Article
- Identification of Hub Genes Related to Liver Metastasis of Colorectal Cancer by Integrative Analysis.Frontiers in oncology · 2021Article
- CXCL8 Associated Dendritic Cell Activation Marker Expression and Recruitment as Indicators of Favorable Outcomes in Colorectal Cancer.Frontiers in immunology · 2021Article
- Activation of TC10-Like Transcription by Lysine Demethylase KDM4B in Colorectal Cancer Cells.Frontiers in cell and developmental biology · 2021Article
- Transcriptomic Differences between Primary Colorectal Adenocarcinomas and Distant Metastases Reveal Metastatic Colorectal Cancer Subtypes.Cancer research · 2019Article
- Integrated multi-omics approach reveals a role of ALDH1A1 in lipid metabolism in human colon cancer cells.Chemico-biological interactions · 2019Article
- Transcriptional Profiling Reveals the Regulatory Role ofFrontiers in genetics · 2019Article
- Circulating inflammatory markers and colorectal cancer risk: A prospective case-cohort study in Japan.International journal of cancer · 2018Article
- GPR56 promotes proliferation of colorectal cancer cells and enhances metastasis via epithelial‑mesenchymal transition through PI3K/AKT signaling activation.Oncology reports · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Colorectal cancer (CRC) is the third most common cancer worldwide and liver metastases are the leading cause of death in patients with CRC. In this study, we performed next-generation sequencing profiling on primary colorectal tumor tissues obtained from three CRC patients with liver metastases and three CRC patients without liver metastases to identify differentially expressed genes (DEGs) that might be responsible for the metastases process. After filtering 2690 DEGs, comprising 996 upregulated and 1694 downregulated RNAs, 22 upregulated and 73 downregulated DEGs were identified. Gene ontology (GO) and pathway analyses were performed to determine the underlying mechanisms. Single-organism process (biological process), cell (cellular component), and binding (molecular function) were the most related terms in the GO analysis. We selected the top 13 upregulated and top 12 downregulated genes by fold change to verify their differential expression using quantitative real-time reverse transcription PCR (qRT-PCR) and immunohistochemistry (IHC). The validation showed that three most significantly upregulated DEGs were HOXD10, UGT2A3, and SLC13A2, whereas the five most significantly downregulated DEGs were SPP1, CXCL8, MMP3, OSM, and CXCL6, respectively. These aberrantly expressed genes may play pivotal roles in promoting or inhibiting metastases. Further studies are required to determine the functions of DEGs to promote the diagnosis of metastases and provide novel chemotherapy targets.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.